Sleepiz

Project "Sleepiz" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Sleep loss is an aggravating factor in the global burden of disease with collateral effects on cardiovascular and mental health as well as injury and death through human error. State of the art clinical diagnostic tools that measure sleep data are expensive, complex to interpret, and stressful for the patients. Today’s most accurate diagnostic tools require patients to strap electrodes and chest monitors to their body and undergo overnight testing, often in a clinic. Sleepiz AG has developed a breakthrough solution in clinical sleep-monitoring solutions. Our innovation, Sleepiz, is a contact-free sensor-based diagnostic device for sleep specialists and clinics. It can analyze patients’ vital signs and environmental measurements without touching the patient. We use test results to continuously feed and improve our self-learning algorithms. Sleep specialists will prescribe Sleepiz to patients to use in their homes. Doctors can view the results remotely and in real-time. We will charge clinics a fee per session in line with today’s diagnostic costs; our solution will be up to 2x more time- and cost-efficient. The approval of Sleepiz as a clinical diagnostic device in the EU and US, together with the ramp-up of commercial activities and stakeholder outreach, comprise the major objectives of this project. The goal of phase 1 is to further validate product-market fits, along with planning and allocating resources for clinical validation trials during phase 2. Sleepiz AG is a Swiss startup comprised of young entrepreneurs and innovators. We have already created great interest: 4 hospitals that use clinical-grade sleep diagnosis tools - a market worth close to €5Bn – want to validate our system. An advisory board of leading experts in related tech and innovation fields will help guide our go-to-market plan. We project annual sales revenues of €34.16M by year 5 after market launch, and we forecast directly creating 197 jobs.